Neuroleptic malignant syndrome after addition of paroxetine to olanzapine.
Kontaxakis
Vassilis P
VP
Havaki-Kontaxaki
Beata J
BJ
Pappa
Dimitra A
DA
Katritsis
Dimosthenis E
DE
Christodoulou
George N
GN
D001569:Benzodiazepines / Q000008:administration & dosage / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008875:Middle Aged; D009459:Neuroleptic Malignant Syndrome / Q000209:etiology*; D000077152:Olanzapine; D017374:Paroxetine / Q000008:administration & dosage / Q000009:adverse effects*; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*
D001569:Benzodiazepines; D000077152:Olanzapine; D017374:Paroxetine; D017367:Selective Serotonin Reuptake Inhibitors